导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 9.26% | 767/4773 |
| 近一周 | -2.23% | 1550/5462 |
| 近一月 | -2.23% | 1208/5421 |
| 近一季 | -9.23% | 3142/5209 |
| 近半年 | -5.08% | 2726/4920 |
| 近一年 | 23.17% | 321/4366 |
| 近两年 | 84.27% | 742/2954 |
| 近三年 | 76.83% | 235/2253 |
| 成立以来 | 47.38% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
7.20% 190/4961 |
10.34% 2423/5312 |
- - |
- - |
| 2025 | 42.75% 691/4813 |
-4.02% 3118/3635 |
3.42% 1013/4076 |
32.04% 1098/4524 |
8.91% 211/4813 |
| 2024 | 23.50% 333/3463 |
13.03% 20/2808 |
5.02% 198/3014 |
8.41% 2751/3129 |
-4.03% 2422/3463 |
| 2023 | -2.93% 615/2656 |
8.72% 447/2280 |
1.03% 247/2385 |
-3.91% 1013/2515 |
-8.03% 2237/2655 |
| 2022 | -11.67% 251/2207 |
-10.68% 411/1919 |
6.16% 758/2016 |
-8.59% 211/2113 |
1.90% 1093/2208 |
| 2021 | 30.63% 66/1822 |
7.98% 66/1255 |
4.13% 918/1330 |
19.25% 55/1466 |
-2.57% 1412/1822 |
| 2020 | 24.02% 640/1250 |
-8.85% 636/1028 |
5.00% 894/1067 |
16.07% 171/1164 |
11.64% 531/1184 |
| 2019 | 23.07% 637/1092 |
24.11% 529/754 |
-5.00% 451/804 |
-3.02% 721/850 |
7.64% 416/918 |
| 2018 | -23.70% 294/834 |
- - |
- - |
- - |
-10.04% 172/691 |
| 2017 | 4.07% 424/714 |
- - |
- - |
- - |
- - |
| 2016 | -10.17% 277/605 |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 鹏华中证一带一路主题指数(LOF)A VS. 长安沪深300非周期A(740101) |